AR065927A1 - Derivados de 5,6-dihidro-1h-piridin-2-ona - Google Patents
Derivados de 5,6-dihidro-1h-piridin-2-onaInfo
- Publication number
- AR065927A1 AR065927A1 ARP080101383A ARP080101383A AR065927A1 AR 065927 A1 AR065927 A1 AR 065927A1 AR P080101383 A ARP080101383 A AR P080101383A AR P080101383 A ARP080101383 A AR P080101383A AR 065927 A1 AR065927 A1 AR 065927A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocyclyl
- alkylene
- aryl
- cycloalkyl
- Prior art date
Links
- 125000000623 heterocyclic group Chemical group 0.000 abstract 11
- 125000003118 aryl group Chemical group 0.000 abstract 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 5
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 150000003973 alkyl amines Chemical class 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000005265 dialkylamine group Chemical group 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 229930194542 Keto Natural products 0.000 abstract 1
- -1 R3 is H Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000468 ketone group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Materials For Medical Uses (AREA)
Abstract
Composiciones farmacéuticas que contienen dichos compuestos que son de utilidad para el tratamiento de infecciones por el virus de hepatitis C. Reivindicacion 1: Un compuesto caracterizado por la formula (1) en donde X es N o CR3, A es (2) o (3),anillo B es arilo o heterociclilo de 6 miembros, opcionalmente sustituido con 1-3 restos R1, en donde R1 es H, halo, nitro, -CHR4-S(O)2R5, -C(S(O)2R5)=CHR4-, -NR5R6, -NR4S(O)2R5, o -NR4S(O)2NR5R6, en donde R4, R5, y R6 son, de modo independiente, H,alquilo C1-6, cicloalquilo C3-8, C(O)O-(alquilo C1-6), arilo, o heterociclilo, o R4 y R5 o R5 y R6 se combinan con los átomos a los que están unidos para formar un anillo heterociclilo de 5 o 6 miembros, R2 es H, alquilo C1-6, cicloalquilo C3-8, -alquilen C1-6-(cicloalquilo C3-8), -alquilen C1-6-(arilo), -alquilen C1-6-(heterociclilo), arilo, o heterociclilo, R3 es H, halo, o alquilo C1-6, Z es -(CR13R14)n-, o O, n es 1 o 2, R7 y R8 son, de modo independiente, H o alquilo C1-6, R9, r10, R11,R12, R13, R14, R15, y R16 son, de modo independiente, H, alquilo C1-6, hidroxi, o halo, en donde los anteriores restos de alquilo, alquileno, arilo, cicloalquilo, o heterociclilo provistos en R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13,R14, R15, y R16 están cada uno opcional e independiente sustituidos con 1-3 sustituyentes seleccionados de alquilamina, amino, arilo, cicloalquilo, heterociclilo, alquilo C1-6, haloalquilo C1-6, hidroxialquilo C1-6, alcoxi C1-6, alquil C1-6-amina,dialquil C1-6-amina, alquenilo c2-6, o alquinilo C2-6, en donde cada uno de los cuales puede estar interrumpido por uno o varios heteroátomos, carboxilo, ciano, halo, hidroxi, ceto, nitro, -C(O)OH, -C(O)NH2, -C(O)(alquil C1-6-amina), -C(O)(dialquilC1-6-amina), -C(O)2-(alquilo C1-6), -C(O)2-(cicloalquilo C3-8), -C(O)2-(arilo), -C(O)2-(heterociclilo), -C(O)2-(alquilen C1-6)arilo, -C(O)2-(alquilen C1-6)heterociclilo, -C(O)2-(alquilen C1-6)cicloalquilo, -C(O)(alquilo C1-6), -C(O)(cicloalquilo C3-8), -(O)(arilo), -C(O)(heterociclilo), -C(O)(alquilen C1-6)arilo, -C(O)(alquilen C1-6)heterociclilo, y -C(O)(alquilen C1-6)cicloalquilo, en donde cada uno de los sustituyentes opcionales anteriores puede estar también opcionalmente sustituido con 1-5 sustituyentes seleccionados de amino, ciano, halo, hidroxi, nitro, alquil C1-6-amina, dialquil C1-6-amina, alquilo C1-6, alcoxi C1-6, alquenilo C1-6, y hidroxialquilo C1-6, en donde cada alquilo está opcionalmente sustituido con uno o variossustituyentes de halo, o una de sus sales o estereoisomeros farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90747807P | 2007-04-03 | 2007-04-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065927A1 true AR065927A1 (es) | 2009-07-08 |
Family
ID=39831340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101383A AR065927A1 (es) | 2007-04-03 | 2008-04-03 | Derivados de 5,6-dihidro-1h-piridin-2-ona |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US7939524B2 (es) |
| EP (1) | EP2129224B1 (es) |
| JP (2) | JP5739662B2 (es) |
| KR (1) | KR101542516B1 (es) |
| CN (2) | CN101677563B (es) |
| AR (1) | AR065927A1 (es) |
| AU (1) | AU2008237364B2 (es) |
| BR (1) | BRPI0809685A2 (es) |
| CA (1) | CA2682584C (es) |
| CL (1) | CL2008000959A1 (es) |
| EA (1) | EA017685B1 (es) |
| ES (1) | ES2578302T3 (es) |
| IL (2) | IL201312A (es) |
| MX (1) | MX2009010564A (es) |
| MY (1) | MY157961A (es) |
| NZ (1) | NZ580445A (es) |
| PE (1) | PE20090220A1 (es) |
| TN (1) | TN2009000398A1 (es) |
| TW (2) | TWI427079B (es) |
| UA (1) | UA100120C2 (es) |
| WO (1) | WO2008124450A1 (es) |
| ZA (1) | ZA200907673B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2656000C (en) | 2006-06-22 | 2016-09-06 | Anadys Pharmaceuticals, Inc. | Pyrro[1,2-b]pyridazinone compounds |
| UA100120C2 (en) | 2007-04-03 | 2012-11-26 | Анадис Фармасьютикалз, Инк. | 5,6-dihydro-1h-pyridin-2-one compounds |
| CN102316871B (zh) | 2008-06-10 | 2014-06-04 | 安那迪斯药品股份有限公司 | [1，2，4]噻二嗪1，1-二氧化合物 |
| EP2346329B1 (en) * | 2008-10-09 | 2013-08-21 | Anadys Pharmaceuticals, Inc. | A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds |
| TW201026675A (en) * | 2008-10-09 | 2010-07-16 | Anadys Pharmaceuticals Inc | 5,6-dihydro-1H-pyridin-2-one compounds |
| CN102858344A (zh) | 2009-10-28 | 2013-01-02 | 安那迪斯药品股份有限公司 | 氘化5,6-二氢-1h-吡啶-2-酮化合物 |
| PH12012501216A1 (en) | 2009-12-18 | 2012-11-05 | Boehringer Ingelheim Int | Hcv combination therapy |
| WO2012158271A1 (en) | 2011-04-06 | 2012-11-22 | Anadys Pharmaceuticals, Inc. | Bridged polycyclic compounds as antiviral agents |
| AU2012268119B2 (en) | 2011-06-07 | 2017-03-02 | Anadys Pharmaceuticals, Inc. | [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid |
| CA2875541A1 (en) * | 2012-06-12 | 2013-12-19 | Patrick F. Smith | Combination of therapeutic agents for treating hcv infection |
| US8816120B2 (en) | 2013-01-14 | 2014-08-26 | Hoffmann-La Roche Inc. | Process for the preparation of N-(4-nitro-2-sulfamoyl-phenyl)-malonamic acid methyl ester and N-(4-amino-2-sulfamoyl-phenyl)-malonamic acid methyl ester |
| LT3421468T (lt) * | 2013-11-13 | 2021-01-11 | Vertex Pharmaceuticals Incorporated | Gripo virusų replikacijos inhibitorių paruošimo būdai |
| WO2016130043A1 (ru) * | 2015-02-13 | 2016-08-18 | Александ Васильевич ИВАЩЕНКО | Бензо[1,2,4]тиадиазиновые ингибиторы репликации вируса гепатита в и фармацевтическая композиция для лечения гепатита в |
| EP3901162A1 (en) | 2016-06-02 | 2021-10-27 | AbbVie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
| BR112020010694A2 (pt) | 2017-12-01 | 2020-11-10 | Abbvie Inc. | agonista de receptor de glicocorticoides e imunoconjugados do mesmo |
| MA55804A (fr) | 2019-04-29 | 2022-04-06 | Solent Therapeutics Llc | Dérivés de 1,1-dioxyde de 3-amino-4h-benzo[e][1,2,4]thiadiazine en tant qu'inhibiteurs de mrgx2 |
| CN113292574B (zh) * | 2020-02-21 | 2022-05-03 | 四川大学 | 一类手性多环的托品烷化合物及其制备方法和用途 |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
| JP7435515B2 (ja) * | 2021-03-17 | 2024-02-21 | 株式会社村田製作所 | 部品収容装置 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4171361A (en) * | 1977-03-31 | 1979-10-16 | Eli Lilly And Company | 1-Substituted-3-amino-6,7-dialkoxy-1H-1,2,4-benzothiadiazine-1-oxides |
| US4889851A (en) * | 1986-11-21 | 1989-12-26 | Fujisawa Pharmaceutical Co, Ltd. | Benzothiadiazine compounds, and pharmaceutical composition comprising the same |
| EP1292310A1 (en) | 2000-05-10 | 2003-03-19 | SmithKline Beecham Corporation | Novel anti-infectives |
| AR036081A1 (es) | 2001-06-07 | 2004-08-11 | Smithkline Beecham Corp | Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos |
| AU2002365198A1 (en) | 2001-10-30 | 2003-07-30 | Smithkline Beecham Corporation | Novel anti-infectives |
| ATE493408T1 (de) * | 2002-11-01 | 2011-01-15 | Abbott Lab | Antiinfektiöse mittel |
| KR20050065670A (ko) | 2002-11-01 | 2005-06-29 | 아보트 러보러터리즈 | 항감염제 |
| US20050075331A1 (en) | 2003-10-06 | 2005-04-07 | Pratt John K. | Anti-infective agents |
| US7601709B2 (en) * | 2003-02-07 | 2009-10-13 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
| TW200602324A (en) * | 2004-03-24 | 2006-01-16 | Janssen Pharmaceutica Nv | Tetrahydro-indazole cannabinoid modulators cross reference to related applications |
| US7439246B2 (en) * | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| JP4624419B2 (ja) * | 2004-08-23 | 2011-02-02 | エフ．ホフマン−ラ ロシュ アーゲー | 抗ウイルス性へテロ環化合物 |
| EA200701297A1 (ru) * | 2004-12-17 | 2007-12-28 | Анадис Фармасьютикалз, Инк. | Соединения пиридазинона |
| WO2006093801A1 (en) * | 2005-02-25 | 2006-09-08 | Abbott Laboratories | Thiadiazine derivatives useful as anti-infective agents |
| RU2007143049A (ru) | 2005-04-21 | 2009-05-27 | Ниппон Синяку Ко., Лтд. (Jp) | Производное фталазинона и содержащая его фармацевтическая композиция |
| JP2008540370A (ja) * | 2005-05-04 | 2008-11-20 | エフ．ホフマン−ラ ロシュ アーゲー | ヘテロ環式抗ウイルス化合物 |
| WO2008051637A2 (en) | 2006-06-22 | 2008-05-02 | Anadys Pharmaceuticals, Inc. | Pyridazinone compounds |
| CA2656000C (en) * | 2006-06-22 | 2016-09-06 | Anadys Pharmaceuticals, Inc. | Pyrro[1,2-b]pyridazinone compounds |
| CL2007003587A1 (es) | 2006-12-12 | 2008-07-04 | Anadys Pharmaceuticals Inc | Compuestos derivados de pirimidinas sustituidas; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para tratar o prevenir la infeccion de la hepatitis c. |
| WO2008073987A1 (en) | 2006-12-12 | 2008-06-19 | Anadys Pharmaceuticals, Inc. | Saturated fused [1,2-b] pyridazinone compounds |
| US20080188466A1 (en) | 2006-12-21 | 2008-08-07 | Anadys Pharmaceuticals, Inc. | Pyridazinone compounds |
| US20080275032A1 (en) | 2006-12-29 | 2008-11-06 | Yuefen Zhou | Pyridazinone compounds |
| US20080227774A1 (en) | 2007-03-15 | 2008-09-18 | Frank Ruebsam | 5,5-disubstituted-indolizinone compounds |
| UA100120C2 (en) | 2007-04-03 | 2012-11-26 | Анадис Фармасьютикалз, Инк. | 5,6-dihydro-1h-pyridin-2-one compounds |
| US7834009B2 (en) | 2007-08-27 | 2010-11-16 | Anadys Pharmaceuticals, Inc. | 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds |
-
2008
- 2008-02-04 UA UAA200910844A patent/UA100120C2/ru unknown
- 2008-04-02 CL CL2008000959A patent/CL2008000959A1/es unknown
- 2008-04-02 MY MYPI20094109A patent/MY157961A/en unknown
- 2008-04-02 WO PCT/US2008/059164 patent/WO2008124450A1/en not_active Ceased
- 2008-04-02 CN CN200880018225.2A patent/CN101677563B/zh not_active Expired - Fee Related
- 2008-04-02 MX MX2009010564A patent/MX2009010564A/es active IP Right Grant
- 2008-04-02 CA CA2682584A patent/CA2682584C/en active Active
- 2008-04-02 EA EA200970916A patent/EA017685B1/ru unknown
- 2008-04-02 ES ES08733076.7T patent/ES2578302T3/es active Active
- 2008-04-02 US US12/061,499 patent/US7939524B2/en active Active
- 2008-04-02 AU AU2008237364A patent/AU2008237364B2/en not_active Ceased
- 2008-04-02 TW TW097111924A patent/TWI427079B/zh not_active IP Right Cessation
- 2008-04-02 CN CN201410217806.6A patent/CN104086540B/zh not_active Expired - Fee Related
- 2008-04-02 NZ NZ580445A patent/NZ580445A/en not_active IP Right Cessation
- 2008-04-02 PE PE2008000597A patent/PE20090220A1/es active IP Right Grant
- 2008-04-02 JP JP2010502271A patent/JP5739662B2/ja not_active Expired - Fee Related
- 2008-04-02 EP EP08733076.7A patent/EP2129224B1/en active Active
- 2008-04-02 BR BRPI0809685A patent/BRPI0809685A2/pt not_active Application Discontinuation
- 2008-04-02 KR KR1020097023036A patent/KR101542516B1/ko not_active Expired - Fee Related
- 2008-04-02 TW TW103101356A patent/TWI481588B/zh not_active IP Right Cessation
- 2008-04-03 AR ARP080101383A patent/AR065927A1/es active IP Right Grant
-
2009
- 2009-09-30 TN TNP2009000398A patent/TN2009000398A1/fr unknown
- 2009-10-01 IL IL201312A patent/IL201312A/en active IP Right Grant
- 2009-11-02 ZA ZA2009/07673A patent/ZA200907673B/en unknown
-
2011
- 2011-03-08 US US13/043,167 patent/US8101800B2/en not_active Expired - Fee Related
-
2012
- 2012-01-23 US US13/356,063 patent/US8236948B2/en not_active Expired - Fee Related
- 2012-08-06 US US13/567,667 patent/US8546602B2/en not_active Expired - Fee Related
-
2013
- 2013-04-11 IL IL225694A patent/IL225694A/en active IP Right Grant
- 2013-09-30 US US14/041,376 patent/US8765741B2/en active Active
-
2014
- 2014-06-10 US US14/300,306 patent/US9156832B2/en not_active Expired - Fee Related
-
2015
- 2015-02-16 JP JP2015027744A patent/JP5934403B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065927A1 (es) | Derivados de 5,6-dihidro-1h-piridin-2-ona | |
| ES2618630T3 (es) | Composiciones terapéuticas y métodos de uso relacionados | |
| PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
| AR054214A1 (es) | Compuestos derivados de 1, 1 - dioxotiadiazina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la infeccion por el virus de la hepatitis c. | |
| ES2515194T3 (es) | Derivados de pirrolidina | |
| PE20091236A1 (es) | Derivados de pirimidina como immunomoduladores de tlr7 | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| ECSP067013A (es) | 2-quinolil-oxazoles sustituidos útiles como inhibidores de pde4 | |
| AR052458A1 (es) | Amino-imidazolonas para la inhibicion de beta-secretasa | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| EA200400615A1 (ru) | Производные амидов в качестве ингибиторов гликогенсинтаза-киназы 3-бета | |
| AR055057A1 (es) | Inhibidores heterociclicos de mek, formas cristalinas de los mismos, procesos para su preparacion y metodos de uso de los mismos en composiciones farmaceuticas y medicamentos para el tratamiento de un trastorno hiperproliferativo o de una condicion inflamatoria. | |
| AR074608A1 (es) | Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas | |
| AR084457A1 (es) | Derivados de biciclo[3,2,1]octilamida | |
| EA200400617A1 (ru) | Гетероариламины в качестве ингибиторов гликогенсинтаза-киназы 3-бета (ингибиторов gsk3) | |
| AR077463A1 (es) | Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| PE20140863A1 (es) | Compuestos de benceno sustituidos con arilo o heteroarilo | |
| AR051202A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
| AR082889A1 (es) | Compuestos y composiciones para la inhibicion de nampt | |
| AR063331A1 (es) | Derivados de biaril eter urea y composiciones farmaceuticas | |
| AR070136A1 (es) | Pirimidil ciclopentanos como inhibidores de la akt proteina quinasa | |
| AR059895A1 (es) | Derivados biciclicos de acidos carboxilicos que resultan de utilidad para tratar trastornos metabolicos | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |